Immunotherapy combinations are just beginning. At the ASH 2015 conference Dr. David Avigan, MD of the Beth Israel Deaconess Medical Center shared his work to use a vaccine with an additional immunotherapy (a PD-1 blocker) and autologous transplant to make the transplant more durable and eliminate minimal residual disease. Learn more about this dendritic cell vaccine, how it works and why the road to immunotherapy will leverage the best available treatments for the best ultimate outcomes.  Thanks to our episode sponsor, Takeda Oncology.